Vitiligo is a common acquired depigmentation disease in the department of dermatology. Its prevalence rate is 0.5% to 2.0% in the world. The clinical manifestation is localized or generalized depigmentation of the skin. The mechanism resulting in the destruction of melanocytes has not been fully elucidated with some academic hypotheses including autoimmune theory, genetic theory, melanocyte self-destruction doctrine and neurochemical factor doctrine, etc. Among them, more and more researches are inclined to that vitiligo is an autoimmune disease. In addition, the role and mechanism of oxidative stress are focused on a hot-spot in the pathogenesis of vitiligo in the department of dermatology. The treatment of vitiligo is a big problem for clinical dermatologists, relating to control the development of leukoderma and promote color recovery of leukoderma. But the effect is relatively slow, the overall curative effect is not satisfied. The treatment options should take into account the area of patient's leukoderma, type, stage, and other factors. The main methods of treatment for vitiligo contain topical drug application and systemic drug administration, phototherapy and photochemotherapy, surgical therapy, etc. New biological agents exhibit good effects in the treatment of vitiligo. With the deepening of vitiligo research and the rapid development of modern medical technology, new treatment methods and ideas emerge in an endless stream.

Vitiligo; Treatment